NEW YORK, July 23 - Viaken has partnered with e-science platform provider InforSense to market and distribute their large-scale genomic analysis and drug discovery platform, the companies announced Monday.
The platform, called the Kensington Discovery Edition, was developed by Copenhagen-based InforSense as networked-based software for data mining and analysis.
Terms of the agreement were not disclosed.
"The Kensington system provides the type of high-end enterprise scale data mining and visualization system that is required to manage and interpret the large volumes of complex data that are generated by today's drug discovery processes," Steve Gardner, chief technical officer of Viaken, said in a statement. "Kensington enables researchers to make more rapid and accurate decisions about R&D projects using a full range of statistical analysis and data mining tools."
Viaken, of Gaithersburg, Md, resells and hosts bioinformatics software applications, providing IT bioinformatics support to customers around the world. Unlike other genomics-related internet hubs, including those offered by DoubleTwist, Compugen, and eBioinformatics, Viaken does not develop proprietary software or content.